Minimum first year sales at $85M AUD pending CFDA approval which is already well in progress. This distributor Boletong have all the right connections including into government, medical institutions and telcos.
Looks like their fantastical revenue figures presented in their pre IPO presentations are looking to be the real deal. The market hasn't believed it to date.
Another medtech stock about to have a serious re-rate.
